Cargando…
The clinical-histologic and prognostic characteristics in patients with a second primary non-small-cell lung cancer after a lobectomy
OBJECTIVES: The goal of this study was to investigate whether an operation can offer survival benefits for patients with a second primary non-small-cell lung cancer (NSCLC) after a lobectomy for a first primary NSCLC and to analyse the characteristics affecting the survival of those patients. METHOD...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521628/ https://www.ncbi.nlm.nih.gov/pubmed/37713470 http://dx.doi.org/10.1093/icvts/ivad155 |
_version_ | 1785110171628863488 |
---|---|
author | Wu, Lei-Lei Wang, Rang-Rang Qian, Jia-Yi Liu, Yu’e Ma, Shang-Shang Li, Ming-Jun Xie, Long-Yan Li, Zhi-Xin Li, Kun Sheng, Bing-Yong Ding, Jun-Rong Xie, Dong |
author_facet | Wu, Lei-Lei Wang, Rang-Rang Qian, Jia-Yi Liu, Yu’e Ma, Shang-Shang Li, Ming-Jun Xie, Long-Yan Li, Zhi-Xin Li, Kun Sheng, Bing-Yong Ding, Jun-Rong Xie, Dong |
author_sort | Wu, Lei-Lei |
collection | PubMed |
description | OBJECTIVES: The goal of this study was to investigate whether an operation can offer survival benefits for patients with a second primary non-small-cell lung cancer (NSCLC) after a lobectomy for a first primary NSCLC and to analyse the characteristics affecting the survival of those patients. METHODS: We performed survival analyses of patients with a second primary NSCLC based on the Surveillance, Epidemiology and End Results program and used propensity score matching to reduce the potential bias and analyse the data. In addition, the primary observational end point was overall survival (OS), and the secondary observational end point was histologic migration. RESULTS: The data from 944 patients were used to perform the main analysis. A total of 36.2% of patients experienced a shift in tumour histologic type between 2 diagnoses of primary NSCLC, and this shift significantly affected OS (P = 0.0065). The median survival time in patients with surgical resection and those without an operation was 52.0 months versus 33.0 months, respectively. Patients with surgical resection at the secondary diagnosis had better survival than those without surgery (5-year OS rate: 48.0% vs 34.0%, P < 0.001). In addition, compared with a pneumonectomy and a sublobar resection, a lobectomy was the optimal surgical procedure for patients diagnosed with a second primary NSCLC after adjusting for other confounders (adjusted hazard ratio: 0.68, P < 0.01). However, in the subgroup analysis, lobar and sublobar resections could provide similar survival benefits for patients with tumour size ≤20 mm (P = 0.5). CONCLUSIONS: The operation, especially a lobectomy, can prolong OS in patients with a second primary NSCLC. Besides, sublobar resection can be performed in selected patients with tumour size ≤20 mm. Moreover, histologic migration may impact the survival of those patients with a secondary primary NSCLC. |
format | Online Article Text |
id | pubmed-10521628 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-105216282023-09-27 The clinical-histologic and prognostic characteristics in patients with a second primary non-small-cell lung cancer after a lobectomy Wu, Lei-Lei Wang, Rang-Rang Qian, Jia-Yi Liu, Yu’e Ma, Shang-Shang Li, Ming-Jun Xie, Long-Yan Li, Zhi-Xin Li, Kun Sheng, Bing-Yong Ding, Jun-Rong Xie, Dong Interdiscip Cardiovasc Thorac Surg Thoracic Oncology OBJECTIVES: The goal of this study was to investigate whether an operation can offer survival benefits for patients with a second primary non-small-cell lung cancer (NSCLC) after a lobectomy for a first primary NSCLC and to analyse the characteristics affecting the survival of those patients. METHODS: We performed survival analyses of patients with a second primary NSCLC based on the Surveillance, Epidemiology and End Results program and used propensity score matching to reduce the potential bias and analyse the data. In addition, the primary observational end point was overall survival (OS), and the secondary observational end point was histologic migration. RESULTS: The data from 944 patients were used to perform the main analysis. A total of 36.2% of patients experienced a shift in tumour histologic type between 2 diagnoses of primary NSCLC, and this shift significantly affected OS (P = 0.0065). The median survival time in patients with surgical resection and those without an operation was 52.0 months versus 33.0 months, respectively. Patients with surgical resection at the secondary diagnosis had better survival than those without surgery (5-year OS rate: 48.0% vs 34.0%, P < 0.001). In addition, compared with a pneumonectomy and a sublobar resection, a lobectomy was the optimal surgical procedure for patients diagnosed with a second primary NSCLC after adjusting for other confounders (adjusted hazard ratio: 0.68, P < 0.01). However, in the subgroup analysis, lobar and sublobar resections could provide similar survival benefits for patients with tumour size ≤20 mm (P = 0.5). CONCLUSIONS: The operation, especially a lobectomy, can prolong OS in patients with a second primary NSCLC. Besides, sublobar resection can be performed in selected patients with tumour size ≤20 mm. Moreover, histologic migration may impact the survival of those patients with a secondary primary NSCLC. Oxford University Press 2023-09-15 /pmc/articles/PMC10521628/ /pubmed/37713470 http://dx.doi.org/10.1093/icvts/ivad155 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Thoracic Oncology Wu, Lei-Lei Wang, Rang-Rang Qian, Jia-Yi Liu, Yu’e Ma, Shang-Shang Li, Ming-Jun Xie, Long-Yan Li, Zhi-Xin Li, Kun Sheng, Bing-Yong Ding, Jun-Rong Xie, Dong The clinical-histologic and prognostic characteristics in patients with a second primary non-small-cell lung cancer after a lobectomy |
title | The clinical-histologic and prognostic characteristics in patients with a second primary non-small-cell lung cancer after a lobectomy |
title_full | The clinical-histologic and prognostic characteristics in patients with a second primary non-small-cell lung cancer after a lobectomy |
title_fullStr | The clinical-histologic and prognostic characteristics in patients with a second primary non-small-cell lung cancer after a lobectomy |
title_full_unstemmed | The clinical-histologic and prognostic characteristics in patients with a second primary non-small-cell lung cancer after a lobectomy |
title_short | The clinical-histologic and prognostic characteristics in patients with a second primary non-small-cell lung cancer after a lobectomy |
title_sort | clinical-histologic and prognostic characteristics in patients with a second primary non-small-cell lung cancer after a lobectomy |
topic | Thoracic Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521628/ https://www.ncbi.nlm.nih.gov/pubmed/37713470 http://dx.doi.org/10.1093/icvts/ivad155 |
work_keys_str_mv | AT wuleilei theclinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy AT wangrangrang theclinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy AT qianjiayi theclinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy AT liuyue theclinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy AT mashangshang theclinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy AT limingjun theclinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy AT xielongyan theclinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy AT lizhixin theclinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy AT likun theclinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy AT shengbingyong theclinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy AT dingjunrong theclinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy AT xiedong theclinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy AT wuleilei clinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy AT wangrangrang clinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy AT qianjiayi clinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy AT liuyue clinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy AT mashangshang clinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy AT limingjun clinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy AT xielongyan clinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy AT lizhixin clinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy AT likun clinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy AT shengbingyong clinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy AT dingjunrong clinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy AT xiedong clinicalhistologicandprognosticcharacteristicsinpatientswithasecondprimarynonsmallcelllungcancerafteralobectomy |